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Brief  2: Strategies for improving service delivery  
and access to services  
Ibis Reproductive Health aims to improve access to 
medication abortion for women around the world. 
Using clinical and social science research, we test 
ways to make protocols and regimens—including 
both mifepristone and misoprostol and misoprostol-
alone options—more user friendly; explore ways to 
improve access to medication abortion services and 
service delivery; and examine global policy related to 
medication abortion. We also strive to improve 
access to medication abortion by providing medically 
accurate information about this service to diverse 
audiences. We work in many different contexts, 
including where abortion is legal and where it is 
restricted, low-resource settings, and places where 
rates of unsafe abortion are high.  
United States 
Evaluating innovative models of service delivery:  
The telemedicine system 
Many states in the US, like Iowa, permit only physicians to 
provide abortions. To address this barrier, Planned Parenthood 
of the Heartland has developed a new technology—a 
telemedicine system referred to as a “lock-box”—that allows 
physicians to dispense mifepristone and misoprostol to women 
from a remote location. Under the physician’s observation 
through an internet video connection, the patient removes the 
drugs from the lock-box and ingests the mifepristone. In 
collaboration with the Abortion Access Project and Planned 
Parenthood of the Heartland, we evaluated this project with the 
goal of creating information that can be used by other provider 
networks nationwide to replicate this model and increase access 
to abortion, particularly in remote areas with no abortion 
providers. Preliminary results from a prospective study 
comparing 221 telemedicine clients and 223 standard provision 
clients at similar gestational ages found similar efficacy and 
adverse event rates in both groups. Telemedicine clients were 
significantly more likely than standard provision clients to have 
an appointment sooner from the time they called (7.6 vs. 10 
days), and more telemedicine clients reported being very 
satisfied with the service (94% vs. 88%) and said they would 
recommend it to a friend (90% vs. 82%). Of telemedicine 
clients, 99% said it was easy to see and hear the doctor; 89% 
felt comfortable asking questions, while 25% would have 
preferred being in the room with the physician. In conclusion, 
this telemedicine provision model is at least as safe, effective, 
and acceptable as the standard model and is a reasonable 
alternative for providing medication abortion at sites with no 
onsite physician.  
Highlights 
 An innovative telemedicine system for dispensing medication abortion 
in the United States has the potential to improve access to abortion for 
women living in states where only physicians are allowed to provide 
abortions. Ibis evaluated this cutting-edge project in the state of Iowa. 
 Ibis supports providers and policymakers in South Africa working to 
improve the quality of second-trimester abortion services and to 
integrate medication abortion into public-sector abortion services. 
 Ibis’s research on the knowledge, opinions, training, and practices of 
health care providers and pharmacists in various regions has identified 
strategies and opportunities for expanding access to abortion through 
provider education. 
Highlighting the need for provider education:  
Curricular reform in ob/gyn residency programs 
The availability of abortion training in ob/gyn residency 
programs and the decisions of residents to avail themselves of 
the training and eventually provide abortion services are critical 
to ensuring continued access to safe and legal abortion in the US. 
With input from Physicians for Reproductive Choice and Health, 
Ibis completed a study that examined abortion training in US 
ob/gyn residency programs. The study was comprised of three 
components: 1) a content analysis of 246 ob/gyn residency 
program websites to examine how abortion training 
opportunities were described; 2) in-depth interviews with 36 
physicians who completed residency in 2007; and 3) a survey of 
approximately 1,000 residents who completed residency in 2006-
2007. The aims of the interviews and surveys with residents were 
to explore their decisions to (or not to) train in abortion care and 
provide abortions, and to better understand the types of 
residency training opportunities available and the policies that 
govern them. Our results reveal significant gaps in the routine 
curricular integration of abortion care in general and medication 
abortion methods in particular. Our website review found that 
only 17.5% of programs offer information on abortion training 
Where we work 
Ibis works in a number of countries in 
diverse contexts, including in Latin 
America and the Caribbean, the 
Middle East and North Africa, sub-
Saharan Africa, and the United States. 
In this brief, we feature work done in 
the United States, South Africa, 
several countries in Latin America, 
and Palestine.  
Ibis Reproductive Health 
South Africa 
Supporting public-sector provision of services:  
Second-trimester abortion 
Despite a progressive abortion law in South Africa, women still 
face significant barriers in accessing abortion care, including 
provider opposition, stigma associated with abortion, and a lack 
of providers trained to perform abortions and facilities certified 
to provide abortions, particularly in rural areas. These barriers 
can result in delays in accessing services and an increase in 
second-trimester abortions. While every effort must be made to 
reduce the need for later abortion in South Africa as morbidity 
and mortality risks increase with gestational age, it is also 
critical that access to high-quality second-trimester services be 
improved. With the Women’s Health Research Unit of the 
University of Cape Town, we are conducting a study 
investigating second-trimester abortion in South Africa’s public 
sector. We have collected data about the procedures used for 
second-trimester abortion, one of which is medication abortion 
with misoprostol, in several public hospitals, as well as data on 
women’s and providers’ knowledge and attitudes regarding 
second-trimester abortion, and are working with the clinical 
and administrative staff of these facilities to improve services. 
Preliminary results from the prospective study with 220 women 
undergoing dilation and evacuation surgical abortion (D&E) 
and 84 women undergoing medication abortion with 
misoprostol reveal that that D&E was significantly more 
effective than misoprostol (99.5% vs. 50.0%), though D&E 
clients had significantly lower gestational ages than misoprostol 
clients (16.0 weeks vs. 18.1 weeks). Complications were 
common with both methods (42.9% vs. 52.4%). D&E required 
significantly less time than misoprostol (median 10 minutes vs. 
18 hours). Significantly more D&E clients compared to 
misoprostol clients reported high or extreme physical pain 
(75.7% vs. 59.5%) and high or extreme emotional discomfort 
(49.5% vs. 33.8%). Overall, clients undergoing both D&E and 
misoprostol procedures were somewhat or very satisfied with 
their experience (94.9% vs. 95.9%) and significantly more D&E 
clients compared to misoprostol clients were somewhat or very 
satisfied with the emotional support they received during the 
procedure (91.7% vs. 78.4%). This is the first comparative 
study of second-trimester abortion techniques in a developing 
country setting. As demonstrated in the US, D&E is more 
effective, requires a shorter hospital stay, and may have fewer 
severe complications. Second-trimester abortion services could 
be improved in South Africa by expanding D&E training, 
altering the cervical priming protocol, improving pain 
management, and introducing mifepristone. We plan to use 
these findings to inform a future randomized controlled trial 
comparing medication to surgical abortion in the second 
trimester.  
Supporting public-sector provision of services:  
Medication abortion 
Mifepristone was approved for use in South Africa in 2001 and 
is currently available in the private sector, but not at free 
government health services. We are working with a coalition of 
local non-governmental and university-based colleagues in 
South Africa to support introduction of mifepristone and 
misoprostol medication abortion into public sector abortion 
services. Our research in collaboration with coalition partners 
has demonstrated that many women in South Africa would be 
early enough in pregnancy (8 weeks) to be eligible for 
medication abortion, and that integration of medication 
abortion in public surgical termination services is feasible. In 
partnership with Ipas and the University of KwaZulu-Natal, we 
opportunities. We recommend enhancing this 
information as a way to contribute to the normalization 
of abortion, and to demonstrate compliance with the 
Accreditation Council for Graduate Medical Education 
requirement to provide “access to experience” in 
induced abortion. See the article Reproductive health and 
cyber (mis)representations: A content analysis of obstetrics and 
gynecology residency program websites by Foster et al. 2008 for 
more information. 
Highlighting the need for expanded access:  
Exploring self-induced abortion outside of the clinic setting 
Recent legal cases, news stories, and clinical case reports have 
highlighted women’s attempts to self-induce their own 
abortions with misoprostol and other methods, raising 
concerns about access to safe and legal abortion services in the 
US. In collaboration with Gynuity Health Projects, we 
conducted a mixed-methods study to better understand 
abortion self-induction in four US cities: Boston, MA; New 
York, NY; San Francisco, CA; and a city in Texas adjacent to 
the US-Mexico border. We conducted surveys with 1,425 
women in primary and reproductive health care clinics serving 
a predominantly low-income population and in-depth 
interviews with 30 women reporting past experience with self-
induction. Women reported using a range of methods; most 
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were ineffective and a few were unsafe. Knowing someone who 
had self-induced was associated with the following factors: 
living in New York or Boston, reporting a barrier to 
reproductive health services, being between 25 and 34 years old, 
receiving government assistance, reporting Latina ethnicity, and 
having a history of two or more prior abortions. Motivations 
for attempting to end their pregnancies on their own included 
desire to avoid a clinic abortion, barriers to accessing a clinic 
abortion, and a preference for self-induction. Other studies 
have shown that women believe medication abortion to be less 
invasive, more private, more natural, and less of a “real” 
abortion; increased access to medication abortion may benefit 
women who value self-induction for these reasons. 
Additionally, we recommend removing restrictions on access to 
abortion care, such as parental involvement laws and funding 
limits, as many women in our study, particularly young women, 
described the cost of abortion as a barrier and chose self-
induction to avoid telling their parents that they needed an 
abortion. One way in which the results of this research are 
being disseminated is through the Misoprostol Alone Working 
Group, an inter-disciplinary group dedicated to this topic and 
convened by Ibis, the Abortion Access Project, Gynuity Health 
Projects, and the National Latina Institute for Reproductive 
Health. See the article Abortion self-induction in the US by 
Grossman et al. 2010 for more information. 
Latin America 
Highlighting the need for provider education:  
Abortion knowledge, attitudes, and practices among Peruvian 
physicians 
Abortion is legal in Peru when a pregnancy endangers a woman’s 
life or health, yet few women are able to access legal abortions for 
these indications. Among other barriers, physicians’ lack of 
knowledge of the law and unwillingness to provide abortions for 
these indications contribute to women’s inability to access legal 
abortion care in Peru. With colleagues at the Centro de 
Promoción y Defensa de los Derechos Sexuales y Reproductivos 
(PROMSEX), the Sociedad Peruana de Obstetricia y Ginecología, 
and the University of California, San Francisco, we surveyed 
physicians attending a workshop on the medical, legal, and ethical 
aspects of legal abortion about their knowledge of abortion 
techniques and abortion’s legal status in Peru, their opinions 
regarding abortion law, their experience with induced abortion, 
and possible ways to improve their training in abortion provision. 
Our findings revealed that physicians were largely willing to 
provide legal abortions, but needed more knowledge, skills, and 
support to be able to do so. We are currently working with 
partners in Peru to address some of these issues by putting into 
place institutional protocols for providing legal abortions. See the 
article Legal abortion in Peru: Knowledge, attitudes and practices among a 
group of physician leaders by Pace et al. 2006 for more information. 
 
Highlighting the need for provider education:  
Physicians’ knowledge and opinions about medication abortion  
In most of Latin America and the Caribbean, abortion is highly 
legally restricted, but research has shown that women frequently 
use misoprostol to self-induce their abortions. With colleagues 
from the Population Council, we conducted a study in 2001-2002 
with physicians from Honduras, Nicaragua, Mexico, and Puerto 
Rico to explore their knowledge and attitudes regarding 
medication abortion. Our findings were that medication abortion 
methods, particularly misoprostol, were used in these countries, 
but that knowledge of regimens and access to quality information 
about the methods were poor. Conflicting opinions regarding 
safety, efficacy, cost, acceptability, and potential for self-
medication emerged, with some physicians voicing concerns 
about self-medication without proper counseling and others 
focusing on the potential for medication abortion to help reduce 
unsafe abortion risks in their countries. These findings are 
important as efforts continue to expand access to safe abortion 
services in Latin America. See the article Physicians’ knowledge and 
opinions about medication abortion in four Latin American and Caribbean 
region countries by Espinoza et al. 2004 for more information. 
are conducting a study to evaluate the 
introduction of medication abortion 
services in public sector facilities in 
KwaZulu-Natal Province, South Africa, 
and assessing the impact on abortion-
seeking behavior and provision. We 
hypothesize that the availability of 
medication abortion might encourage 
women to attend services sooner, and 
increase the capacity of existing facilities 





to serve more women. We hope that this 
new study will generate additional data 
that will support roll-out of medication 
abortion by the National Department of 
Health and will inform implementation 
of new guidelines for publicly funded, 
free medication abortion services. See 
the articles Medical abortion: The possibilities 
for introduction in the public sector in South 
Africa by Cooper et al. 2005, Medication 
Highlighting the need for provider education:  
Pharmacists’ knowledge and provision of medical 
abortifacients 
Though abortion is legally restricted in most of Latin America 
and the Caribbean, research suggests that many women obtain 
misoprostol from pharmacies without a prescription and self-
induce their abortions. We conducted a study in a large Latin 
American city to learn more about pharmacists’ knowledge 
and provision of medical abortifacients, including misoprostol. 
Through interviews with staff at pharmacies and mystery client 
visits, we learned that while abortifacient provision was 
common, knowledge about appropriate use of abortifacients 
was low and few pharmacy staff recommended an effective 
misoprostol dosing regimen to their clients. Improving training 
for pharmacy staff is important, particularly in legally 
restricted, developing country settings like this one where 
many women access treatment advice from pharmacy staff. 
See the article Pharmacy provision of medical abortifacients in a Latin 
American city by Lara et al. 2006 for more information. In 
addition to this research, we worked with colleagues in Latin 
America at the Federación Latinoamericana de Sociedades de 
Obstetricia y Ginecología and PROMSEX to collect 
information about misoprostol availability in different Latin 
American countries. See the article Availability and obstetric use of 
misoprostol in Latin American countries by Távara-Orozco et al. 
2008 for more information.  
abortion in the private sector in South 
Africa by Blanchard et al. 2006, and 
Integrating medical abortion into safe 
abortion services: Experience from three 
pilot sites in South Africa by Kawonga 
et al. 2008 for more information. 
 
In Latin America, some women obtain misoprostal in pharmacies, 
like this one in Mexico City, to induce their own abortions. 
Ibis Reproductive Health aims to 
improve women’s reproductive 





Ibis Reproductive Health 
Middle East and North 
Africa 
Highlighting the need for 
provider education: 
Pharmacists’ knowledge and 
provision of misoprostol in Palestine 
The creation of the wall in the West 
Bank, restrictions on freedom of 
movement, and enforcement of the 
Jerusalem identity card and permit 
system have severely disrupted 
Palestinian women’s access to health 
facilities and contributed to increased 
rates of unintended pregnancy. As 
pharmacists play an important role in 
health service delivery in this region, 
Ibis conducted a study to examine the 
availability of misoprostol for early 
pregnancy termination at pharmacies. 
We conducted interviews with at least 
one pharmacist at 87 retail pharmacies 
in eight West Bank cities, which 
represented approximately 15% of all 
retail pharmacies in the West Bank. Our 
interviews included questions on 
misoprostol knowledge, availability, and 
provision patterns. We asked 
pharmacists about community and 
clinician awareness of misoprostol and 
the need for misoprostol among specific 
groups. Pharmacists expressed concern 
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about the high rate of contraceptive 
failure and unintended pregnancy among 
women. Over three-quarters of the West 
Bank pharmacists in our study reported 
that women have come to the pharmacy 
seeking misoprostol for pregnancy 
termination and nearly 70% of these 
pharmacists reported that there has been 
a considerable increase in requests for 
misoprostol since the year 2000. 
Pharmacists reported varied knowledge 
about the misoprostol regimen for early 
pregnancy termination. Access to 
abortion and reproductive health services 
cannot be separated from the broader 
context of occupation. However, our 
study points to several avenues for 
expanding access to safe abortion 
services, including misoprostol-only 
education campaigns targeting 
pharmacists and clinicians. 
Ibis interviewed pharmacists in the eight West Bank 
cities indicated above to examine the availability of 
misoprostol for early pregnancy termination.  
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